case_images: PMC9867573_01
case_images: Clinical courses of two cases who treated with taxane-based chemotherapy and enfortumab vedotin. The details of the clinical course are described in the main text. Both patients are alive, and EV treatment is ongoing. Yellow arrows indicate metastatic lesions. Abbreviations: GCa: gemcitabine and carboplatin combination chemotherapy; GC: gemcitabine and cisplatin combination chemotherapy; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin combination chemotherapy; Pem: pembrolizumab; EV: enfortumab vedotin; PG: paclitaxel and gemcitabine combination chemotherapy; PN: paclitaxel and nedaplatin combination chemotherapy; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
case_images: CRIU2023-1024239.002.jpg
case_images: PMC9867573_02_CRIU2023-1024239.002.jpg
case_images: fig2
case_images: After 20 cycles of PN, multiple lung metastases progressed; however, he developed hearing impairment due to platinum agents (Figure 2(b)). The metastatic lesions became undetectable (complete response) after four cycles of EV (Figure 2(b)).
case_images: PMC9867573_02
case_images: Clinical courses of two cases who treated with taxane-based chemotherapy and enfortumab vedotin. The details of the clinical course are described in the main text. Both patients are alive, and EV treatment is ongoing. Yellow arrows indicate metastatic lesions. Abbreviations: GCa: gemcitabine and carboplatin combination chemotherapy; GC: gemcitabine and cisplatin combination chemotherapy; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin combination chemotherapy; Pem: pembrolizumab; EV: enfortumab vedotin; PG: paclitaxel and gemcitabine combination chemotherapy; PN: paclitaxel and nedaplatin combination chemotherapy; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
case_images: CRIU2023-1024239.002.jpg
case_images: PMC9867573_02_CRIU2023-1024239.002.jpg
case_images: fig2
case_images: After 20 cycles of PN, multiple lung metastases progressed; however, he developed hearing impairment due to platinum agents (Figure 2(b)). The metastatic lesions became undetectable (complete response) after four cycles of EV (Figure 2(b)).